ALEC
NASDAQ
$1.54
Alector Inc (ALEC)
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $3.10 (+101.30%)
Market Cap
$167M
Beta (5Y)
1.66
Price Chart
Valuation
Market Cap$167M
Forward P/E8.47
P/S9.04
P/B14.86
Profitability
Total Revenue (TTM)$18M
Gross Profit (TTM)-$89M
EBITDA-$130M
Operating Margin-2382%
EPS-$1.17
Financial Health
Debt-to-Equity94.1%
Growth & Risk
EPS 5Y CAGR-14.47%
Revenue 5Y CAGR+0.42%
FCF 5Y CAGR-1.79%
Beta (5Y)1.66
Sharpe Ratio0.49